Advances in Hematology

Research Article

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

Table 2

Summary of the CD4 T cell responses to the Sp17 peptides by DLBCL patients.


Patients	MHC class II status	Sp17 protein	-IFN response to peptides per 50,000 cells
Patients	MHC class II status	Sp17 protein	Sp17(4)	Sp17(5)	Sp17(6)	No peptide	HIV-1	PHA

Significant response
1	DRB0102,1104	+
2	DRB0101,0701	+
5	DRB0301,0401	−
8	DRB1501,0803	ND
10	DRB0101	ND
12	DRB0401,1401	+
14	DRB1403,0401	ND
18	DRB0401,0401	+
No significant response
7	DRB0301,0701	+
9	DRB0301,1601	−
15	DRB1301,1101	ND
19	DRB0401,0901	+
20	DRB1104,1501	+
21	DRB0301,1303	+
39	DRB0701	−
43	DRB0101,1101	−
48	DRB0101,0405	−

DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant -IFN responses are highlighted in bold. ND, not determined.